Combined-Modality Therapy for Bladder Cancer

ONCOLOGY

Volumn 11, Issue 9 SUPPL., 1997, Pages 18-26

  McCaffrey, John A ^a   Bajorin, Dean F ^a   Scher, Howard I ^a   Bosl, George J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; EPIRUBICIN; METHOTREXATE; VINBLASTINE; PROTEIN P53; RETINOBLASTOMA PROTEIN;

ARTICLE; BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CYSTECTOMY; HUMAN; LYMPH NODE METASTASIS; MULTIMODALITY CANCER THERAPY; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TUMOR LOCALIZATION; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; GENETICS; METABOLISM; METASTASIS; PATHOLOGY; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; SURVIVAL;

CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; CYSTECTOMY; HUMANS; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS; RETINOBLASTOMA PROTEIN; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS;

EID: 0031226329     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Scher HI, Shipley WU, Herr HW: Cancer of the bladder, in DeVita VT, Hellman S, Rosenberg SA, (eds): Cancer Principles and Practice of Oncology, 5th ed. pp 1300-1321. Philadelphia, Lippincott-Raven, 1996.
2. Whitmore WF Jr, Marshall VF: Radical total cystectomy for cancer of the bladder' 230 consecutive cases five years later. J Urol 87:853-868, 1962.
3. Richie JP, Skinner DG, Kaufman JJ, et al: Radical cystectomy for carcinoma of the bladder: 16 years of experience. J Urol 113:186-189, 1975.
4. Bredael JJ, Croker BP, Glenn JF, et al: The curability of invasive bladder cancer treated by radical cystoprostatectomy. Eur Urol 6:206-210, 1980.
5. Pearse J, Reed RR, Hodges CV, et al: Radical cystectomy for bladder cancer. J Urol 119:216-218, 1978.
6. Whitmore WF Jr: Management of invasive bladder neoplasms. Semin Urol 1:34-41, 1983.
7. Smith JA Jr, Whitmore WF Jr: Regional lymph node metastasis from bladder cancer. J Urol 126:591-593, 1983.
8. Giulani L, Giberti C, Martorana G, et al: Results of radical cystectomy for primary bladder cancer: Retrospective study of more than 200 cases. Urology 26:243-248, 1985.
9. Pagano F, Bassi P, Galetti TP, et al: Results of contemporary radical cystectomy for invasive bladder cancer: A clinical pathological study with emphasis on the inadequacy of tumor, nodes and metastases classification. J Urol 145:45-50, 1991.
10. Wishnow KI, Tenney DM: Will Rogers and the results of radical cystectomy for invasive bladder cancer. Urol Clin North Am 18:529-537, 1991.
11. Lerner SP, Skinner E. Skinner DG, et al: Radical cystectomy in regionally advanced bladder cancer. Urol Clin North Am 19:713-724, 1992.
12. Soloway MS, Lopez AE, Patel J, et al: Results of radical cystectomy for transitional cell carcinoma of the bladder and the effect of chemotherapy. Cancer 73:1926-1931, 1994.
13. Seemann O, Junemann KP, Alken P: Patient selection criteria for orthotopic bladder replacement, in Webster GD, Goldwasser B, (eds): Urinary Diversion: Scientific Foundations and Clinical Practice, pp 14-17. Oxford, Isis Medical Media, 1995
14. Sweeney P, Kursh ED, Resnick MI, et al. Partial cystectomy. Urol Clin North Am 19:10701-10711, 1992.
15. Scher HI, Herr HW, Sternberg CN, et al: Neo-adjuvant chemotherapy for invasive bladder cancer: Experience with the M-VAC regimen. Br J Urol 64:250-256, 1989.
16. Herr HW: Conservative management of muscle-infiltrating bladder cancer: Prospective experience. J Urol 138:1162-1163, 1987.
17. Henry K, Miller J, Mori M, et al: Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol 140:964-967, 1988.
18. Kata EJ, Herr HW: The role of transurethral resection for muscle invasive bladder carcinoma. J Urol 149(suppl):316A, 1993.
19. Jenkins BJ, Caulfield MJ, Fowler CG, et al: Reappraisal of the role of radical radiotherapy and salvage cystectomy in the treatment of invasive (T2-3) bladder cancer. Br J Urol 62:343-346, 1988.
20. Shearer RJ, Chilvers CE, Bloom HJ, et al: Adjuvant chemotherapy in T3 carcinoma of the bladder. Br J Urol 62:558-564, 1988.
21. Gospodarowicz M, Hawkins NV, Rawlings GA, et al: Radical radiotherapy for muscle invasive transitional cell carcinoma of the bladder: Failure and analysis. J Urol 142:1448-1454, 1989.
22. Mamegen H, Fisher R, Mameghan J, et al: Analysis of failure following definitive radiotherapy for invasive transitional cell carcinoma of the bladder. Int J Radiat Oncol Biol Phys 31:247-254, 1995.
23. DeNeve W, Lybeert ML, Goor C, et al: Radiotherapy for T2 and T3 carcinoma of the bladder: Influence of overall treatment time. Radiother Oncol 36:183-188, 1995
24. Scher HI: Chemotherapy for invasive bladder cancer: Neoadjuvant vs. adjuvant. Semin Oncol 17:555-565, 1990.
25. Scher HI, Sternberg CN: Chemotherapy of urologic malignancies. Semin Urol 3:239-280, 1985
26. Loehrer P, Einhorn LH, Elson PJ, et al: A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative group study. J Clin Oncol 12:1066-1073, 1992.
27. Logothetis CJ, Dexeus F, Sella A, et al: A prospective randomized trial comparing CisCA to M-VAC chemotherapy in advanced metastatic urothelial tumors. J Clin Oncol 8:1050-1055, 1990.
28. Harker WG, Meyers FJ, Freiha FS, et al: Cisplatin, methotrexate and vinblastine (CMV): An effective chemotherapy regimen for metastatic transitional cell carcinoma of the urothelial tract A Northern California Oncology Group study. J Clin Oncol 3:1463-1470, 1985.
29. Mead GM, Crook AM, Russell JM, et al: An MRC randomized trial comparing MV (methotrexate and vinblastine) with CMV (cisplatin + MV) for metastatic transitional cell cancer (abstract). Proc Am Soc Clin Oncol 15:600, 1996
30. Sternberg CN, Yagoda A, Scher HI, et al: M-VAC for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer 64:2448-2458, 1989.
31. Schultz P, Herr HW, Zhang ZF, et al: Neoadjuvant chemotherapy for invasive bladder cancer: Prognostic factors for survival of patients treated with M-VAC with five years follow-up. J Clin Oncol 12:1394-1401, 1994.
32. Scher HI: Chemotherapy for invasive bladder cancer: Neoadjuvant vs adjuvant. Semin Oncol 17:555-565, 1990.
33. Parmar MK: Neoadjuvant chemotherapy in invasive bladder cancer. Trial design. Prog Clin Biol Res 353:115-118, 1990.
34. Merrin C, Beckley S: Adjuvant chemotherapy for bladder cancer with doxorubicin hydrochloride and cyclophosphamide: Preliminary report. J Urol 119:62-63, 1978
35. Clyne CA, Jenkins JD, Smart CJ, et al: A trial of adjuvant chemotherapy for stage T3 bladder tumors. J Urol 129:736-737, 1983
36. Richards B, Bastable JR, Freedman L, et al: Adjuvant chemotherapy with doxorubicin (Adnamycin) and 5-fluorouracil in T3, NX, MO bladder cancer treated with radiotherapy. Br J Urol 55:386-391, 1983.
37. Skinner DG, Daniels JR, Lieskovsky G, et al. Current status of adjuvant chemotherapy after radical cystectomy by local resection and methotrexate. Br J Urol 56:46-52, 1984.
38. Socquet Y: Surgery and adjuvant chemotherapy with high-dose methotrexate and folinic acid rescue for infiltrating tumors of the bladder. Cancer Trent Rep 65:187-189, 1981.
39. Logothetis CJ, Johnson DE, Chong C, et al: Adjuvant cyclophosphamide, doxorubicin and cisplatin chemotherapy for bladder cancer: An update. J Clin Oncol 6:1590-1596, 1988.
40. Freiha FS, Reese J, Torti FM, et al: A randomized trial of radical cystectomy versus radical cystectomy plus cisplatin, vinblastine and methotrexate chemotherapy for muscle-invasive bladder cancer. J Urol 152:495-500, 1996.
41. Studer UE, Bacchi M, Biederman C, et al: Adjuvant cisplatin chemotherapy following cystectomy for bladder cancer: Results of a prospective randomized trial. J Urol 152:81-84, 1994
42. Stockle M, Meyenburg W, Welleck S, et al. Advanced bladder cancer (stages pT3b, pT4a, pN1 and pN2): Improved survival after radical cystectomy and 3 adjuvant cycles of chemotherapy. Results of a controlled prospective study. J Urol 148:302-307, 1992.
43. Skinner DG, Daniels JR, Russel CA, et al: The role of adjuvant chemotherapy following cystectomy for invasive bladder cancer' A prospective comparative trial. J Urol 145:459-467, 1991.
44. Stockle M, Meyenberg W, Wellek S, et al: Adjuvant polychemotherapy of nonorgan-confined bladder cancer after radical cystectomy revisited. Long-term results of a controlled prospective study and further clinical experience. J Urol 153:47-52, 1995.
45. Vogelzang NJ, Moormeier JA, Awan AM, et al: Methotrexate, vinblastine, doxorubicin and cisplatin followed by radiotherapy or surgery for muscle invasive bladder cancer' The University of Chicago experience. J Urol 149:753-757, 1993.
46. Sternberg CN, Arena MG, Calabresi F, et al: Neoadjuvant M-VAC (methotrexate, vinblastine, doxorabicin and cisplatin) for infiltrating transitional cell carcinoma of the bladder Cancer 72:1975-1982, 1993
47. Tannock I, Gospodarowicz M, Connolly J, et al: M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) chemotherapy for transitional cell carcinoma: The Princess Margaret Hospital experience. J Urol 142:289-292, 1989.
48. Herr HW, Scher HI: Neoadjuvant chemotherapy and partial cystectomy for invasive bladder cancer. J Clin Oncol 12:975-980, 1994
49. Housset M, Maulard C, Chretien YC, et al: Combined radiation and chemotherapy for invasive transitional cell carcinoma of the bladder: A prospective study. J Clin Oncol 11:2150-2157, 1993.
50. Steineck G, Scher HI: Integrated therapy for advanced bladder cancer. Curr Opin Urol 4:281-286, 1994.
51. Scher HI, Norton L: Chemotherapy for urothelial tract malignancies: Breaking the deadlock. Semin Surg Oncol 8:316-341, 1992.
52. Hall R: Neoadjuvant CMV chemotherapy and cystectomy or radiation in muscle-invasive cancer: First analysis of MRC/EORTC intercontinental trial (abstract). Proc Am Soc Clin Oncol 15:612, 1996
53. Wallace DM, Raghavan D, Kelly KA, et al: Neo-adjuvant (pre-emptive) cisplatin therapy in invasive transitional cell carcinoma of the bladder. Br J Urol 67:608-615, 1991.
54. Martinez-Pineiro JA, Jimenez Leon J, Gonzalez Martin M, et al: Neoadjuvant cisplatinum in locally advanced urothelial bladder cancer: A prospective randomized study of the group CUETO, in Splinter TAW, Scher HI, (eds). Neoadjuvant Chemotherapy in Invasive Bladder Cancer, pp 95-103, New York, Wiley-Liss, 1990.
55. Rintala E, Hannisdal E, Fossa SD, et al: Neoadjuvant chemotherapy in bladder cancer: A randomized study: Nordic Cystectomy Trial I. Scand J Urol Nephrol 27:355-362, 1993.
56. Scher HI, Herr HW, Sternberg CN, et al: M-VAC (methotrexate, vinblastine, Adriamycin and cisplatin) and bladder preservation, in Splinter TAW, Scher HI, (eds): Neoadjuvanr Chemotherapy of Invasive Bladder Cancer, pp 179-186. New York, Wiley-Liss, 1990.
57. Sternberg CN, Pansadoro V, Lauretti S, et al: Neo-adjuvant M-VAC (methotrexate, vinblastine, adriamycin and cisplatin) chemotherapy and bladder preservation for muscle infiltrating transitional cell carcinoma of the bladder. Urol Oncol Clin 1:127-133, 1995.
58. Paz-Ares L, Lianes P, Diaz-Puente M, et al: Neoadjuvant chemotherapy aiming at bladder preservation (abstract). Third international Congress on Neo-adjuvant Chemotherapy, p 34. Paris, February 69, 1991.
59. Srougi M, Simon SD: Primary methotrexate, vinblastine, doxorubicin and cisplatin chemotherapy and bladder preservation in locally invasive bladder cancer: A five year follow-up. J Urol 151:593-597, 1994.
60. Hunis A, Levin M, Turek A, et al: Modified M-VAC as neoadjuvant chemotherapy in bladder cancer, the one year later report (abstract). Proc Am Soc Clin Oncol 11:598, 1992.
61. Amiel J, Quintens H, Thyss A, et al: Combination transurethral resection and systemic chemotherapy as primary treatment of infiltrating bladder tumors (pT2-pT4NXM0). J Urol 94:333-336, 1988.
62. Simon SD, Srougi M, Neoadjuvant MVAC chemotherapy and partial cystectomy for treatment of locally invasive transitional cell carcinoma of the bladder, in Splinter TAW, Scher HI, (eds): Neoadjuvant Chemotherapy of Invasive Bladder Cancer, pp 169-173. New York, Wiley- Liss, 1990.
63. Sternberg CN, Pansadoro V: Bladder-preserving treatments: Chemotherapy and conservative surgery, in Vogelzang NJ, Scardino PT, Shipley WU, et al, (eds): Comprehensive Textbook of Genitourinary Oncology, pp 522-531. Baltimore, Williams & Wilkins, 1996.
64. Sternberg CN, Raghavan D, Ohi Y, et al: Neo-adjuvant and adjuvant chemotherapy in locally advanced disease: What are the effects on survival and prognosis? Int J Urol 2:76-88, 1995.
65. Kaufman DF, Shipley WU, Griffin PP, et al: Selective preservation by combination treatment of invasive bladder cancer. N Engl J Med 329:1377-1382, 1993.
66. Coppin C, Gospodarowicz M, Dixon P, et al: Improved local control of invasive bladder cancer by concurrent cisplatin and preoperative or radical radiation (abstract). Proc Am Soc Clin Oncol 11:668, 1992.
67. Dunst J, Sauer R, Schrott KM, et al: Organsparing treatment of advanced bladder cancer: A ten-year experience. Int J Radiat Oncol Biol Phys 30:261-266, 1994.
68. Sauer R, Dunst J, Altendorf-Hoffman A, et al: Radiotherapy with or without cispiatin in bladder cancer. Int J Radiat Oncol Biol Phys 19:687-691, 1990.
69. Tester W, Caplan R, Heaney J, et al: Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: Results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol 14:119-126, 1996.
70. Kachnic LA, Kaufman DS, Zietman AL, ct ah Selective bladder preservation by combined modality therapy for invasive bladder cancer (abstract). Int J Radiat Oncol Biol Phys 1:271, 1995.
71. Given RW, Parsons JT, McCarley D, et al: Bladder-sparing multimodality treatment of muscle-invasive bladder cancer- A five-year followup. Urology 46:499-505, 1995.
72. Tester W, Porter A, Asbell S, et al: Combined modality program with possible organ preservation for invasive bladder carcinoma: Results of RTOG protocol 85-Int J Radiat Oncol Biol Phys 25:783-790, 1993.
73. Lowe S: p53 dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74:957-967, 1993.
74. Bajorin DF, Sarkis AS, Reuter V, et al: Invasive bladder cancer treated with neoadjuvant M-VAC: The relationship of p53 nuclear overexpression with survival (abstract). Proc Am Soc Clin Oncol 13:655, 1994.
75. Esrig D, Elmajain D, Groshen S, et al: Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331:1259-1264, 1994.
76. Cordon-Cardo C, Wartinger D, Petrylak D, et al: Altered expression of the retinoblastoma gene product: Prognostic indicator in bladder cancer. J Natl Cancer Inst 84:1251-1256, 1992.
77. Logothetis CJ, Xu H, Ro JY, et al: Altered expression of retinoblastoma protein and known prognostic variables in locally advanced bladder cancer. J Natl Cancer Inst 84:1256-1261, 1992.